AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 OCT 23 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Tumor cells made to express CD154 can enhance anticancer activity via several avenues, researchers report.
A growing interest in cancer vaccine technology has lead to the development of novel gene therapies that can stimulate immune system response to tumor cells. A new study performed by researchers in Europe indicates cancer cells transduced with adenoviral vectors encoding for CD154 can trigger cancer-specific immunity by activating patients' dendritic cells and sparking interferon production.
Angelica Loskog and colleagues at the University of Uppsala in Sweden collaborated with others from the Medical University of Lubeck in Germany to examine the characteristics of CD154-transduced human bladder cancer cell lines and transduced patient renal cell carcinoma cells.
Investigators assessed the effects of therapy on the cells grown alone and when grown in the presence of patients' dendritic cells. They also evaluated CD154 gene therapy in animal models.
"Human bladder cancer cell lines expressing CD154 showed a decreased growth rate, increased apoptosis, and modulated expression of molecules important for recognition by cytotoxic lymphocytes," stated Loskog and coauthors.
In addition, the transduced cancer cells initiated dendritic cell maturation and caused lymphocytes cocultured with dendritic cells ...
Source: HighBeam Research, Cancer cells made to express CD154 prompt strong anticancer activity.